Amyloid β (Reverse Human, 16-10)

<strong>Amyloid β (Reverse Human, 16-10)</strong> <strong>Catalog number:</strong> B2024168 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 1 mg <strong>Molecular Weight or Concentration:</strong> 940.01 g/mol <strong>Supplied as:</strong> Lyophilized Powder <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> −20°C <strong>Keywords:</strong> Amyloid beta, Aβ, Amyloid beta peptide, Amyloid beta protein, Beta-amyloid, A4 protein, Alzheimer's beta peptide, Amyloid precursor protein fragment <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Selkoe, D. J. (2001). Alzheimer's disease: genes, proteins, and therapy. *Physiological Reviews*, 81(2), 741-766. 2. Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science*, 297(5580), 353-356. 3. Haass, C., & Selkoe, D. J. (2007). Soluble and insoluble beta-amyloid: a key role for protofibrils in Alzheimer's disease. *The American Journal of Pathology*, 171(1), 1-5. 4. Karran, E., & Walker, L. (2013). The amyloid cascade hypothesis: are we poised for success? *Nature Reviews Drug Discovery*, 12(10), 751-752. 5. Selkoe, D. J. (2012). Alzheimer's disease: a central role for amyloid. *Nature Reviews Neuroscience*, 13(8), 494-504. 6. Zlokovic, B. V. (2011). Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. *Nature Reviews Neuroscience*, 12(12), 933-948. 7. De Strooper, B., & Karran, E. (2016). The cellular phase of Alzheimer's disease. *Cell*, 164(4), 603-615. 8. Cummings, J. (2016). The role of biomarkers in Alzheimer's disease drug development. *Nature Reviews Drug Discovery*, 15(5), 327-328. 9. Vellas, B., et al. (2017). Designing drug trials for Alzheimer's disease: a new approach. *Nature Reviews Drug Discovery*, 16(1), 1-2. 10. Bateman, R. J., et al. (2012). Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *New England Journal of Medicine*, 367(9), 795-804. <a href="Amyloid β (Reverse Human">https://pubmed.ncbi.nlm.nih.gov/?term=Amyloid β (Reverse Human</a> <br><strong>Products Related to Amyloid β (Reverse Human, 16-10) can be found at</strong> <a href="https://moleculardepot.com/product-category/Peptides/"> Peptides</a>